Clin2
NCT07713498Possibly a fitEnrolling by invitation

Lowering inhaled steroids for tezepelumab-treated asthma patients

Severe Asthma

Part of Immune system & allergy, Lungs & breathing clinical trials.

This trial looks at whether people with severe asthma who are taking the biologic tezepelumab can safely reduce their use of inhaled corticosteroids (ICS). It aims to see if reducing or stopping ICS affects asthma symptoms or flare-ups.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
61 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older.
  • You have been diagnosed with severe asthma.
  • You have received or are scheduled to receive at least one dose of tezepelumab.
  • You are willing to come to Franciscus hospital if you have an asthma flare-up.
  • You understand Dutch or English well enough to follow the study instructions.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07363642Recruiting· Phase 3
Tezepelumab for severe asthma

This study tests a drug called tezepelumab for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve symptoms.

Beijing
NCT06705764Recruiting· Phase 4
Tezepelumab for asthma attacks in the emergency room

This trial tests if a drug called Tezepelumab can help adults with asthma who visit the emergency room. It aims to reduce severe asthma attacks and improve breathing control.

Edmonton, Alberta
NCT07735494Recruiting
Physical activity study for people with severe asthma starting tezepelumab

This study tests whether a physical activity program can help people with severe asthma achieve better control and reduce flare-ups when added to a new treatment called tezepelumab.

Leeds
NCT07757841Not yet recruiting
Real-world treatment of allergic bronchopulmonary aspergillosis with tezepelumab

This study looks at how well the drug tezepelumab works in treating allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common fungus. It may help reduce asthma symptoms and flare-ups in people with severe asthma related to ABPA.

Jinan, Shandong
NCT07013123Not yet recruiting· Phase 3
Testing sublingual allergy tablets with tezepelumab for severe asthma

This trial tests if adding house dust mite allergy tablets (Acarizax) to tezepelumab (Tezspire) helps adults with severe allergic asthma stay in control. It is for people who are still struggling with asthma despite current treatments.

NCT06023589Recruiting· Phase 3
Testing tezepelumab for kids with severe asthma

This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.

Montgomery, Alabama

Hear when a new Severe Asthma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.